Results 131 to 140 of about 93,929 (247)

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. [PDF]

, 2014
Activating mutations in FLT3 confer poor prognosis for individuals with acute myeloid leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered by acquired resistance and ...
He, Bai-Liang, He, Bai-Liang, Lasater, Elisabeth A, Leung, Anskar Yh, Lin, Kimberly, Lopez, Michael S, Shah, Neil P, Shokat, Kevan M, Smith, Catherine C, Warkentin, Alexander A   +9 more
core  

Irradiated Liver Cancer Cell Vaccine Transfected With GM‐CSF Induces Specific and Long‐Lasting Anti‐tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM‐CSF

Cell Proliferation, EarlyView.
Song et al. developed an mGM‐CSF‐loaded, liver cancer cell‐based vaccine that potently activated dendritic cells and elicited tumour‐specific T cell responses. Mechanistically, radiation‐induced oxidative damage to mitochondrial DNA in cancer cells triggers the cGAS‐STING pathway in DCs, which synergizes with mGM‐CSF‐driven JAK2‐STAT3 signalling to ...
Zhiruo Song, Yujie Jiang, Yu Zhang, Danyi Ao, Chunjun Ye, Xiya Huang, Yingqiong Zhou, Hanle Yang, Ruolan Xia, Jiayuan Ai, Dandan Wan, Aiping Tong, Yuquan Wei, Xuemei He, Aqu Alu, Xiawei Wei   +15 more
wiley   +1 more source

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma

Advanced Science
Rapid development of resistance to sorafenib and subsequent hyperprogression in patients with advanced hepatocellular carcinoma (HCC) pose significant challenges, with the underlying mechanisms still largely unknown.
Xu‐Yan Wang, Yuan Liao, Rui‐Qi Wang, Yi‐Tong Lu, Ying‐Zhe Wang, Yu‐Qi Xin, Dong‐Ming Kuang, Xiang‐Ming Lao, Junying Xu, Zhi‐Ling Zhou, Kunhua Hu   +10 more
doaj   +1 more source

Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways

iScience
Summary: Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), unfortunately encounters resistance in most patients, leading to disease progression.
Hugang Li, Zirui Ye, Xun Wang, Jianlan Yuan, Jingyi Guo, Chen Liu, Bin Yan, Haiming Fan, Yi Lyu, Xiaoli Liu   +9 more
doaj   +1 more source

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

Hepatology Research, EarlyView.
Hepatocellular carcinoma (HCC) is a common type of liver cancer. Recently, combination therapy with atezolizumab plus bevacizumab has become a standard systemic treatment for patients with unresectable HCC. Some HCCs show high signal intensity on the hepatobiliary phase of Gd‐EOB‐DTPA–enhanced MRI.
Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masakatsu Tsurusaki, Keitaro Sofue, Yoshihiko Yano, Hidenori Toyoda, Atsushi Hiraoka, Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki, Norio Itokawa, Masanori Atsukawa, Kazuhito Kawata, Kazuto Tajiri, Joji Tani, Toru Ishikawa, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Takashi Kumada, Naoshi Nishida, Yuzo Kodama   +24 more
wiley   +1 more source

Five Advances in the Last 50 Years: Liver Malignancies

World Journal of Surgery, EarlyView.
Alex B. Blair, Timothy M. Pawlik
wiley   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma: A Case Report

Gut and Liver, 2010
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe.
doaj   +1 more source